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Abstract
Objectives: Repeat transarterial chemoembolization (TACE) is a common intervention performed for
hepatocellular carcinoma (HCC). The aim of this study was to identify predictors of the need for repeat
TACE.
Methods: Between 2008 and 2012, data on patient and tumour variables were collected for 262 patients
treated with a first TACE procedure for HCC. The decision to perform repeat TACE procedures was made
at the completion of the first TACE or after follow-up imaging demonstrated the subtotal treatment of HCC
tumours.
Results: Repeat TACE was performed in 67 of 262 (25.6%) patients. Necrosis of HCC, measured after
the first TACE, was lower in patients who subsequently received repeat TACE (P = 0.042). On multivariable
analysis, total tumour diameter of >5 cm [odds ratio (OR) 2.76, 95% confidence interval (CI) 1.45–5.25;
P = 0.002] and increasing age (OR 1.04/year, 95% CI 1.00–1.07; P = 0.030) were predictive of the need
for repeat TACE. Measures of liver function and TACE approach (selective versus non-selective) were not
predictive of repeat TACE. Median survival did not differ significantly between patients who did (median
survival: 21.1 months) and did not (median survival: 26.1 months) receive a repeat TACE procedure
(P = 0.574).
Conclusions: The requirement for repeat TACE is associated with older age, increased HCC tumour
burden and subtotal TACE-induced HCC necrosis. Importantly, repeat TACE was not associated with
reduced survival.
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Introduction
Hepatocellular carcinoma (HCC) is a common primary liver
malignancy in the USA and worldwide, and is the leading cause of
death among patients with cirrhosis.1 Although HCC is the sixth
most common neoplasm in the world, its dismal prognosis
makes it the third leading cause of cancer-related mortality and
responsible for approximately 600 000 deaths per year.2 The inci-
dence of HCC in the USA has tripled in the past two decades and
5-year survival rates remain as low as 10–15%.3
The most widely utilized staging system for HCC is the Barce-
lona Clinic Liver Cancer (BCLC) staging system.4,5 This system
distinguishes five tumour stages and links the stages to different
treatment options. It is estimated that 70% of patients with HCC
are diagnosed at intermediate (BCLC stage B) to advanced (BCLC
stage C) tumour stages, at which treatment options are limited.4,5
Numerous studies and reviews have attempted to determine the
best strategy for treating patients with intermediate-stage HCC
(BCLC stage B and C) who are not candidates for potentially
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curative therapies.6–9 For patients with large (>5 cm) or multifocal
HCC without macrovascular invasion or extrahepatic metastasis,
transarterial chemoembolization (TACE) is the recommended
treatment modality based on high-quality randomized clinical
trials,10,11 and a meta-analysis of randomized controlled trials.12
Current practice guidelines from the American Association for the
Study of Liver Disease (AASLD) recommend TACE as a first-line
non-curative therapy for non-surgical patients with large or
multifocal HCC who do not have vascular invasion or extrahe-
patic spread.13,14 An alternative locoregional therapy for this
patient population is radioembolization.15,16
The administration of TACE is common. An analysis of the
Surveillance, Epidemiology and End Results (SEER) database
reported that TACE is the single most common oncologic inter-
vention for HCC in the USA.17 Furthermore, a review of the
Scientific Registry of Transplant Recipients (SRTR) data on liver
transplantation for HCC demonstrates that TACE is the most
common bridging therapy and is offered to >70% of waitlisted
HCC patients in the USA.18
One common problem facing clinicians is subtotal HCC
tumour necrosis (partial response) following a single TACE treat-
ment. These patients are most commonly treated with repeat
TACE interventions, although the efficacy of repeat TACE is
unclear. Furthermore, there is a need to better define patient
populations that may benefit from additional TACE procedures.
The primary aim of this study was to determine independent
risk factors associated with repeat TACE treatment in patients
with intermediate- to advanced-stage HCC at a single university-
based hospital. The secondary aim was to measure the efficacy of
repeat TACE.
Materials and methods
Ethical approval for this study was obtained from the University of
Alabama (UAB) Institutional Review Board (protocol no.
X100310006). A retrospective chart review was performed for all
patients receiving TACE at UAB between 2008 and 2012.
Patient population
Patients were diagnosed with HCC according to the AASLD
criteria. The decision to offer TACE to patients with HCC was
made by a multidisciplinary liver tumour board at UAB that
included medical oncologists, surgeons, hepatologists and
interventional radiologists. Patient candidacy for TACE was
guided by established AASLD practice guidelines.13,14 Transarterial
chemoembolization was administered as previously described.19
The decision to perform additional TACE procedures was made
either at the completion of the first TACE because the HCC
tumour(s) was considered by the interventional radiologist to
have been subtotally treated (referred to as ‘planned repeat TACE’)
or after follow-up imaging suggested the subtotal treatment of
lesions or the appearance of new lesions (referred to as ‘unplanned
repeat TACE’).
A list of all patients treated with TACE as an initial oncologic
therapy was generated from the UAB interventional radiology
procedures electronic database. Patients submitted to TACE were
excluded if they had a non-HCC tumour type. Patients with
recurrent HCC following liver resection or transplantation were
also excluded. In addition, patients with HCC tumours that had
been treated previously with another locoregional therapy such as
radiofrequency ablation or external beam radiotherapy were
excluded. Patients taking chemotherapeutic agents before and
after the procedure were not excluded.
Radiographic measurements
Diagnosis of HCC
Hepatocellular carcinoma was diagnosed according to the pres-
ence of an arterially enhancing lesion of 1–2 cm in size with portal
venous washout and pseudocapsule formation on delayed-phase
imaging, or an arterially enhancing lesion of >2 cm in size with
portal venous washout or pseudocapsule formation on delayed-
phase imaging.20,21
Tumour necrosis in HCC
Tumour response was assessed according to mRECIST (modified
response evaluation criteria in solid tumours) as previously
described.19,22 Response data are presented for the largest lesion
only, herein referred to as the index lesion. There are four catego-
ries of tumour response according to mRECIST, which indicate,
respectively: complete response; partial response; stable disease,
and progressive disease.23 Because TACE most commonly results
in a partial response as defined by mRECIST19 and because the
partial response category includes a large range of response (30–
99%), mRECIST partial response is presented in three subcatego-
ries according to data granularity: 30–60%; 60–90%, and 90–99%.
Sarcopoenia
Psoas cross-sectional area was used as a surrogate marker of fra-
gility.24 The area of the right and left psoas muscle was measured
at the level of the fourth lumbar vertebral body and a region of
interest was drawn around the borders of the psoas muscle. The
enclosed region was then used to calculate the cross-sectional area
of the psoas muscle.
Cirrhosis
A caudate to right lobe ratio of >0.9,25,26 nodular transformation
of the liver, and sequela of portal venous hypertension27 were used
as radiographic indicators of cirrhosis.
Data analysis
Data on patient demographics, clinical history, laboratory find-
ings and HCC tumour characteristics were collected. To allow for
the use of common statistical procedures, the analysis was
restricted to examination of the index HCC tumour, which was
defined as the largest tumour (the use of more than one tumour
per patient in the analysis would have violated the common
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assumption of independent data observations). When the data
followed a normal distribution, a two-sample t-test was used to
compare group means. When the normality of the data distribu-
tion was questionable, the non-parametric Wilcoxon rank sum
test was used to compare group distributions. The primary ana-
lytic approach for dichotomous variables utilized chi-squared
analysis. Kaplan–Meier curves were constructed to evaluate
patient survival. Survival probabilities were analysed using the
log-rank test. For all inferences, the probability of a type I error
(α) was set to 0.05. All analyses were conducted using sas Version
9.2 (SAS Institute, Inc., Cary, NC, USA).
Results
Patient demographics
Data for a total of 262 patients treated with either single or multi-
ple TACE(s) as locoregional therapy for HCC were reviewed. A
single TACE procedure was performed in 194 (74.3%) and multi-
ple TACE procedures were performed in 67 (25.7%) patients. The
median time between TACE procedures was 1.83 months
[interquartile range (IQR) 1.31–4.34 months]. The repeat TACE
group included 53 (79.1%) patients who underwent two TACE
procedures, 12 (17.9%) patients who underwent three TACE pro-
cedures, and two (3.0%) patients who underwent four TACE pro-
cedures. Figure 1 depicts the distribution of HCC patients treated
with TACE stratified by unifocal versus multifocal disease, TACE
vehicle [lipiodol versus drug-eluting beads (DEBs)], and the deliv-
ery of single versus multiple TACE treatments.
Patients in the repeat TACE group were older and less likely to
have hepatitis C. All patients had underlying liver disease,
although 11.4% of those in the single TACE group and 6.1% of
those in the multiple TACE group did not have cirrhosis appreci-
able by laboratory or radiology criteria (Table 1).
Planned repeat TACE versus unplanned repeat TACE
Planned repeat TACE procedures were performed in 20 of 67
(29.9%) HCC patients. The previous HCC tumour was retreated
in 10 patients, different HCC tumours were treated in four
patients, and a combination of previous and different HCC
tumours were treated in the remaining six patients. The control of
HCC tumours was achieved in nine of 20 (45.0%) patients, in
three of whom control was achieved by TACE alone. In the other
six, control was achieved by repeat TACE plus additional poten-
tially curative therapies. Complete response, as defined by
mRECIST, was not achieved in six patients submitted to more
than one TACE procedure. The remaining five patients received
more than one TACE treatment, but were non-compliant with
follow-up recommendations.
Unplanned repeat TACE procedures were performed in the
remaining 47 of the 67 (70.1%) HCC patients in the repeat TACE
group. The previous HCC tumour was retreated in 30 patients,
different HCC tumours were treated in 10 patients, and a combi-
nation of previous and different HCC tumours were treated in the
remaining seven patients. Tumour control was achieved in 16 of
47 (34.0%) patients, in seven by TACE alone, and in the remainder
by repeat TACE plus additional potentially curative therapies.
Tumour control was not achieved in 30 patients who received
more than one TACE treatment. The remaining patient was
treated with more than one TACE procedure but was non-
compliant with follow-up recommendations.
Tumour necrosis in HCC
Hepatocellular carcinoma tumour necrosis was measured in all
patients following the first TACE procedure (Fig. 2). There were
significant differences in the distribution of HCC necrosis
between patients treated with one and those treated with more
than one TACE procedure (P = 0.042).
Predictors of repeat TACE
Univariate and subsequent multivariate analyses for risk factors
for repeat TACE are shown in Table 2. A sensitivity analysis was
performed to see if predictors of repeat TACE varied based upon
whether the TACE was planned or unplanned. These analyses
demonstrated that total tumour diameter was the dominant pre-
dictor of planned repeat TACE, whereas age was the dominant
predictor of unplanned repeat TACE.
Survival
Median survival did not differ significantly between patients who
did (median survival: 21.1 months) and did not (median survival:
26.1 months) receive repeat TACE procedures (P = 0.574) (Fig. 3).


























Figure 1 Flow chart depicting the distribution of unifocal and
multifocal hepatocellular carcinoma (HCC), the use of lipiodol versus
drug-eluting beads (DEBs), and the administration of one versus
more than one transarterial chemoembolization (TACE) procedure
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transplantation, although the differences in survival remained
non-significant (one TACE: 19.5 months; more than one TACE:
20.1 months; P = 0.612).
Discussion
The most clinically significant findings demonstrated in this study
are that advancing age and increasing total tumour burden are
associated with need for repeat chemoembolization for inter-
mediate to advanced HCC. Patients submitted to repeat TACE
were more likely to experience inferior HCC tumour necrosis after
the first TACE treatment. Importantly, survival did not differ
between patients who received one TACE and those who received
more than one TACE. This equivalent survival suggests that efforts
to obtain more complete HCC tumour necrosis by using repeat
TACE treatments do not result in increased mortality and may
improve overall survival.
The association between advancing age and repeat TACE
probably reflects a negative patient selection bias. Older patients
are often not considered candidates for other more invasive and
potentially curative locoregional or surgical interventions (such
as liver transplantation). Transarterial chemoembolization is an
ideal cross-sectional intervention which allows for the observa-
tion of older HCC patients over time to establish how they tol-
erate the first TACE before decisions about repeat TACE are
made.
The association between increasing total tumour diameter and
repeat TACE is predictable. A finite amount of chemotherapy and
embolic material is administered in each TACE and thus a greater
tumour volume might be expected to require additional TACE
Table 1 Baseline demographics in 262 patients with hepatocellular carcinoma treated with transarterial chemoembolization (TACE)
Variable Single TACE group Multiple TACE group P-value
(n = 195) (n = 67)
Age, years, mean ± SD 61.1 ± 9.2 64.6 ± 9.4 0.009
Male, n (%) 141 (72.3%) 54 (80.6%) 0.179
Race, n (%) 0.875
Black 39 (20.2%) 15 (23.1%)
White 147 (76.2%) 48 (73.9%)
Aetiology of liver diseasea, n (%)
Alcohol 47 (24.2%) 17 (25.4%) 0.851
HBV 12 (6.2%) 6 (9.0%) 0.413
HCV 109 (56.2%) 27 (40.3%) 0.025
NASH 42 (21.5%) 12 (17.9%) 0.526
Pre-TACE laboratory values
Laboratory MELD score 11.1 ± 3.8 11.3 ± 3.9 0.659
α-fetoprotein, ng/ml, median (IQR) 16.1 (5.69–155.00) 29.1 (9.54–227.00) 0.268
Δ Sarcopoenia −5.5 ± 9.0 −5.2 ± 8.7 0.853
Tumour characteristics
Number of tumours, median (percentiles 25–75) 1.0 (1.00–2.00) 2.0 (1.00–3.00) 0.023
Size of largest tumour, cm, mean ± SD 3.6 ± 2.5 4.6 ± 2.7 0.028
Total tumour diameterb, cm, mean ± SD 5.0 ± 3.9 6.7 ± 3.7 0.003
Type of TACE, n (%)
Lipiodol 100 (51.3%) 38 (56.7%) 0.442
Drug-eluting beads 92 (47.2%) 29 (43.3%) 0.581
Non-selective (lobar) TACE 13 (6.7%) 5 (7.5%) 0.840
Post-TACE interventionsc, n (%)
Ablation 34 (17.4%) 16 (23.9%) 0.247
Radiation therapy 39 (20.0%) 11 (16.4%) 0.519
Liver transplantation 40 (20.5%) 5 (7.5%) 0.015
aSome patients had liver disease of more than one aetiology.
bSum of axial diameters of three largest lesions.
cSome patients had more than one post-TACE intervention.
HBV, hepatitis B virus; HCV, hepatitis C virus; IQR, interquartile range; MELD, Model for End-stage Liver Disease (range: 6–40); NASH, non-alcoholic
steatohepatitis; SD, standard deviation.
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procedures to achieve adequate HCC tumour necrosis. This
concept is demonstrated nicely in Fig. 2, which shows that a lower
overall percentage of HCC necrosis following the first TACE pro-
cedure was observed in patients who subsequently underwent
additional TACE procedures. The mRECIST protocol defines
HCC necrosis as the percentage of non-enhancing tumour of
tumour volume.23 Even with an equivalent volume of tumour
necrosis, it is readily apparent how a larger denominator would
result in a lower percentage of HCC necrosis. In addition, a larger
total tumour diameter was correlated with the presence of both
multifocal tumours and bilobar tumours, each of which would be
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Figure 2 Necrosis of hepatocellular carcinoma (HCC) tumour(s) following first transarterial chemoembolization (TACE) procedure, quantified
according to mRECIST. Data above each bar show the percentages of patients meeting the respective mRECIST response; data within each
bar show the number of patients used to calculate the percentage response. Patients who received one TACE procedure experienced better
HCC tumour necrosis than patients treated with more than one TACE procedure (P = 0.042)
Table 2 Univariate and multivariable analyses of predictors of repeat transarterial chemoembolization (TACE)
Univariate analysis Multivariate analysis
OR (95% CI) P-value OR (95% CI) P-value
More than one tumour 1.92 (1.08–3.40) 0.026
HCC tumour size >3 cm 2.52 (1.20–5.30) 0.015
Total tumour diameter >5 cm 2.82 (1.52–5.27) 0.001 2.76 (1.45–5.25) 0.002
Central position (vs. peripheral) 1.09 (0.54–2.22) 0.806
α-fetoprotein >400 ng/ml 0.89 (0.41–1.94) 0.764
Age (per year) 1.04 (1.01–1.08) 0.008 1.04 (1.00–1.07) 0.030
Child–Pugh class A (vs. B/C) 1.13 (0.65–1.97) 0.671
MELD score (per point) 1.02 (0.95–1.09) 0.653
Platelet count >100 0.89 (0.51–1.55) 0.676
Sarcopoenia 1.00 (0.97–1.04) 0.854
Lipiodol (vs. DEBs) 0.80 (0.46–1.41) 0.442
Selective TACE (vs. non-selective) 1.12 (0.38–3.26) 0.840
95% CI, 95% confidence interval; DEBs, drug-eluting beads; HCC, hepatocellular carcinoma; MELD, Model for End-stage Liver Disease (range: 6–40);
OR, odds ratio.
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Few other studies in the literature have examined the efficacy of
repeat TACE procedures. Two recent studies conducted in Austria
report a scoring system that predicts risk factors for poor survival
following repeat TACE procedures.28,29 The Assessment for
Retreatment with TACE (‘ART’) score is derived from clinical
measurements obtained after the initial TACE treatment, and
includes transaminasaemia (reflecting an increase in the level of
aspartate aminotransferase of >25%), worsening liver function
(increase in Child–Pugh score), and the absence of a radiologic
tumour response to initial TACE as independent negative prog-
nostic factors for overall survival following a second TACE.28,29
Prospective studies of liver function following TACE demonstrate
that significant transaminasaemia and significant liver dysfunc-
tion are rare,22,30,31 which limits the applicability of the ART score.
As with all retrospective studies, the present report has several
limitations. The first of these refers to patient selection bias, which
derives from the fact that older patients are preferentially consid-
ered for repeat TACE rather than other locoregional or surgical
therapeutic options. Secondly, the risk factors for repeat TACE
identified in this study are fairly intuitive and these published
findings may not significantly impact on current TACE practice.
The limited generalizability of all single-centre TACE studies rep-
resents another limitation and reflects significant inter-centre
variation in patient candidacy, TACE vehicle (lipiodol or DEBs
and type of DEBs), and technical approaches (lobar, selective,
sub-selective). This variation is further highlighted by the fact that
the frequency of re-TACE in the current series was much lower
than that in most published studies. Regardless of these limita-
tions, this is one of the few studies to identify pre-TACE risk
factors for repeat TACE and the fact that the study participants
represent an HCC population spanning a period of only 4.5 years
suggests its relevancy to current practice.
In conclusion, advanced age and increasing total tumour diam-
eter were identified as independent risk factors for repeat TACE.
Patients undergoing repeat TACE experienced significantly lower
HCC tumour necrosis following the initial TACE. Survival did not
differ significantly between HCC patients submitted to one TACE
and those submitted to more than one TACE procedure. Specific
analysis of repeat TACE recipients demonstrates that repeat TACE
is an efficacious intervention that should be considered for
patients in whom subtotal HCC tumour necrosis is achieved fol-
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